Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials
暂无分享,去创建一个
Deepak L. Bhatt | M. Price | H. White | G. Stone | K. Mahaffey | R. Harrington | P. Steg | D. Angiolillo | C. Hamm | C. Gibson | J. Prats | Tiepu Liu
[1] Marc P. Bonaca,et al. Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.
[2] D. Angiolillo,et al. Novel antiplatelet agents in acute coronary syndrome , 2015, Nature Reviews Cardiology.
[3] R. Schulz,et al. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. , 2014, Journal of the American College of Cardiology.
[4] Deepak L. Bhatt,et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data , 2013, The Lancet.
[5] M. Krucoff,et al. Electrocardiographic Safety of Cangrelor, a New Intravenous Antiplatelet Agent: A Randomized, Double-blind, Placebo- and Moxifloxacin-controlled Thorough QT Study , 2013, Journal of cardiovascular pharmacology.
[6] D. Angiolillo,et al. Cangrelor: a review on pharmacology and clinical trial development , 2013, Expert review of cardiovascular therapy.
[7] Gregg W Stone,et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. , 2013, The New England journal of medicine.
[8] David J Cohen,et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. , 2013, JAMA.
[9] Deepak L. Bhatt,et al. A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention: The INNOVATE-PCI Trial , 2012, Circulation. Cardiovascular interventions.
[10] D. Angiolillo,et al. Antithrombotic Therapy in Patients With Chronic Kidney Disease , 2012, Circulation.
[11] Deepak L. Bhatt,et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials , 2012, Journal of Thrombosis and Thrombolysis.
[12] M. Sabatine,et al. Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. , 2012, Journal of the American College of Cardiology.
[13] Sunil V. Rao,et al. Bleeding and acute coronary syndromes: defining, predicting, and managing risk and outcomes. , 2011, Current Drug Targets.
[14] Davide Capodanno,et al. Antithrombotic therapy in the elderly. , 2010, Journal of the American College of Cardiology.
[15] D. Angiolillo,et al. Impact of race and gender on antithrombotic therapy , 2010, Thrombosis and Haemostasis.
[16] Sunil V. Rao,et al. The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. , 2010, Journal of the American College of Cardiology.
[17] M. Cavender,et al. Bleeding associated with current therapies for acute coronary syndrome: What are the mechanisms? , 2010, Journal of Thrombosis and Thrombolysis.
[18] Gregg W Stone,et al. Platelet inhibition with cangrelor in patients undergoing PCI. , 2009, The New England journal of medicine.
[19] Deepak L. Bhatt,et al. Intravenous platelet blockade with cangrelor during PCI. , 2009, The New England journal of medicine.
[20] J. Ware,et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. , 2009, European heart journal.
[21] A. Kastrati,et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. , 2008, Journal of the American College of Cardiology.
[22] S. Yusuf,et al. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.
[23] K. Alexander,et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. , 2005, JAMA.
[24] E. Antman,et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (E , 2005, American heart journal.
[25] H. White,et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. , 2004, American heart journal.
[26] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.